Skip to main
ALZN

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc. has recently demonstrated promising progress in its clinical developments, notably with the positive top-line results from its studies announced in June 2023. The company's innovative pipeline, which includes two unique therapeutic candidates targeting neurodegenerative diseases, positions it favorably within the biopharmaceutical sector. Additionally, the current attractive valuation suggests significant potential upside, underscoring the potential for achieving key milestones to act as catalysts for future stock performance.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million for the period, translating to an earnings per share (EPS) of $(1.28), which was significantly worse than the previous estimates of $(0.69). The company faces considerable risks that could undermine its share price, including challenges related to balance sheet liquidity, the efficacy and safety of its product candidates in clinical trials, and the regulatory approvals required for commercialization. Additionally, external factors such as competition in the biopharmaceutical sector, macroeconomic conditions, and shifts in healthcare priorities may further complicate the company's ability to achieve financial success.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.